What is Insitro?
Insitro is at the forefront of revolutionizing drug development by integrating advanced machine learning techniques with comprehensive biological data. The company's core mission is to decode the complexities of human biology to deliver more effective treatments to patients at an accelerated pace. By synthesizing diverse datasets, including in vitro cellular data and human clinical information, Insitro aims to gain deeper insights into disease mechanisms and identify novel therapeutic targets. Their multidisciplinary approach, combining expertise in life sciences, data science, and engineering, positions them as a key player in the biopharmaceutical innovation landscape.
How much funding has Insitro raised?
Insitro has raised a total of $643M across 3 funding rounds:
Series A
$100M
Series B
$143M
Series C
$400M
Series A (2019): $100M with participation from GV, Two Sigma Ventures, ARCH VENTURE PARTNERS, Third Rock Ventures, Verily, Bezos Expeditions, Mubadala, and Foresite Capital
Series B (2020): $143M led by Andreessen Horowitz, WuXi AppTec, T. Rowe Price Associates, BlackRock, HOF Capital, CPP Investments, and Casdin Capital
Series C (2021): $400M supported by Andreessen Horowitz, Casdin Capital, BlackRock, GV, HOF Capital, Third Rock Ventures, Two Sigma Ventures, ARCH VENTURE PARTNERS, CPP Investments, Alexandria Venture Investments, Foresite Capital, and T. Rowe Price Associates
Key Investors in Insitro
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, consumer products, and frontier technology innovations. They provide financial backing to promising startups and growth-stage businesses globally.
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for investing in technology companies across various stages. They provide strategic guidance and capital to foster innovation and growth in the tech sector.
BlackRock
BlackRock is a global investment management firm offering a comprehensive range of investment products and services. They provide investment management, risk management, and advisory services to institutional and individual investors worldwide.
What's next for Insitro?
With its recent major strategic investment, Insitro is well-positioned to further scale its operations and advance its pipeline of therapeutic programs across critical areas such as metabolism, oncology, and neuroscience. The substantial capital infusion will likely fuel continued investment in their proprietary data generation platforms and advanced analytical capabilities. This strategic financing is expected to enable Insitro to deepen its research efforts, expand its team of scientists and engineers, and accelerate the translation of its data-driven insights into tangible clinical advancements, reinforcing its trajectory as a leader in data-centric drug discovery.
See full Insitro company page
